Darbepoetin Alfa (Aranesp) Market: Strong Growth Anticipated as Demand for Effective Anemia Treatments Rises, Market Innovations Lead the Way

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Darbepoetin Alfa (Aranesp) Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $7.11 billion In 2028 At A CAGR Of 4.8%.

The darbepoetin alfa (aranesp) market size has grown strongly in recent years. It will grow from $5.56 billion in 2023 to $5.88 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to anemia treatment advancements, erythropoiesis-stimulating agents (esa) demand, biopharmaceutical innovation, clinical acceptance, improved patient outcomes.

The darbepoetin alfa (aranesp) market size is expected to see steady growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to healthcare reimbursement policies, increased awareness and education, healthcare infrastructure development, renal care demands, aging population. Major trends in the forecast period include global market penetration, digital health integration, personalized treatment approaches, adoption of biosimilars, long-acting formulations.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp

Darbepoetin Alfa (Aranesp) Market Major Segments
The darbepoetin alfa (aranesp) market covered in this report is segmented -

1) By Type: Epogen, Procrit, Aranesp, Other Types
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Patients with Chronic Kidney Disease, Patients with Cancer, Other Applications

Key Driver - Rising Chronic Disease Burden Fuels Growth In Darbepoetin Alfa Market

The increase in the prevalence of chronic diseases is expected to propel the growth of the darbepoetin alfa market going forward. A chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Darbepoetin alfa is used to treat various chronic diseases, to reverse chemotherapy-induced anemia in cancer. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least one chronic condition would increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, an increase in the prevalence of chronic diseases is driving the growth of the darbepoetin alfa market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=12171&type=smp

Prominent Trend - Oral Darbepoetin Alfa Alternative Fuels Innovation In Chronic Anemia Treatment

Product innovations are a key trend gaining popularity in the darbepoetin alfa market. Major companies operating in the darbepoetin alfa market are adopting new technologies to sustain their position in the market. For instance, in February 2023, GlaxoSmithKline. Ltd, a UK-based pharmaceutical and biotechnology company, introduced the US Food and Drug Administration (FDA), a US-based government agency that approved Jesduvroq (daprodustat). Daprodustat, recombinant human erythropoietin (rhEPO, darbepoetin alfa or epoetin alfa), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor and is used once daily treatment of anemia brought on by chronic kidney disease (CKD) in people who have been on dialysis for at least four months.

Darbepoetin Alfa (Aranesp) Market Players
Major companies operating in the darbepoetin alfa (aranesp) market report are Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Iko Pharmaceutical Co. Ltd., Menagen Pharmaceutical Industries, Kyowa Kirin Co. Ltd., Polifarma S.p.A.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the darbepoetin alfa market in 2023. The regions covered in the darbepoetin alfa (aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Darbepoetin Alfa (Aranesp) Market Report Structure
3. Darbepoetin Alfa (Aranesp) Market Trends And Strategies
4. Darbepoetin Alfa (Aranesp) Market - Macro Economic Scenario
5. Darbepoetin Alfa (Aranesp) Market Size And Growth
…..
27. Darbepoetin Alfa (Aranesp) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.